BASTIDE LE CONFORT overview

Caissargues, July 25, 2024 Groupe Bastide announced today that it has set up a new financing contract for €375 million, including a syndicated loan and a revolving credit facility, as part of its proactive debt management strategy. The new loan replaces both the €270.5 million syndicated loan set up in November 2021 (maturing in November 2026) and a €38.8 million bilateral loan. The new syndicated loan comprises a first tranche of €35 million, repayable over 5 years from July 2025, a...

Caissargues, May 15, 2024 In € millions 2022-2023 published 2022-2023* restated 2023-2024 published Change vs. restated 3 rd quarter revenue 130.7 124.5 134.7 +8.2% 9-month revenue 380.2 367.3 395.2 +7.6% *2022-2023 revenue restated for the scope related to the sale of Distrimed on December 4, 2023 and of Sodimed and Promefa – Swiss entities in the process of being sold (see sales reconstitution in appendix). Sale of Homecare business in Switzerland in progress Groupe Bastide announced that...

Caissargues, April 8, 2024 Present in the United Kingdom home oxygen therapy market, since the acquisition of Baywater Healthcare in 2018, Bastide has announced that it has been appointed by the NHS (National Health Service) as the exclusive operator for Respiratory Care (oxygen therapy) in the East of England region in the United Kingdom. This new seven-year contract, extendable to ten years, will bring additional revenue of around €10 million a year. Groupe Bastide will begin operating in...

Caissargues, March 20, 2024 In € millions - Year ended June 30 H1 2022-2023 H1 2023-2024 Change Revenue 249.7 265.0 +6.1 % EBITDA * 49.9 53.6 +7.5 % EBITDA margin 20.0% 20.2% Recurring operating profit 21.5 21.9 +2.1% Recurring operating margin 8.6% 8.3% Operating profit 18.9 20.7 +9.5% Financial result -6.9 -11.9 Taxes -3.7 -5.1 Net profit from continuing operations 8.3 3.6 -56.6% Net loss from discontinued operations -5.7 -1.2 Net profit, Group share 2.6 2.4 -7.7% * EBITDA: recurring...

Caissargues, February 15, 2024 In €m 2022-2023 2023-2024 Organic growth Published growth Q1 revenue 119.5 127.9 +5.2% +7.0% Q2 revenue 129.9 137.1 +6.1% +5.5% H1 revenue (at December 31 st ) 249.4 265.0 +5.7% +6.2% Business remained buoyant in the second quarter, with organic growth 1 accelerating to 6.1%, compared with 5.2% in the first quarter. Revenue over the period saw an overall climb of 5.5% to €137.1 million This performance includes €0.6 million in contributions from companies...

Caissargues, December 4, 2023 Groupe Bastide announced today the sale of its Distrimed subsidiary to Hygie31, a European specialist in consulting and support for healthcare networks, majority-owned by investment fund Latour Capital, with BPI France as a minority shareholder. Hygie31 has 1,060 member pharmacies, including the Pharmacie Lafayette banner. A 70%-owned subsidiary of Groupe Bastide, Distrimed is a major player in online sales of medical devices to healthcare professionals. In...

Caissargues, November 16, 2023 In € millions 2022-2023 published 2022-2023* restated 2023-2024 published Change First-quarter revenue (at September 30) 122.0 119.5 127.9 +7.0% * Revenue restated for Livramedom revenue, Livramedom having been sold in May 2, 2023, for better comparability Groupe Bastide posted a solid first-quarter performance, with revenue up 7.0% to €127.9 million. This performance benefited from €2.4 million in contributions from companies acquired over the past year, in...